Pharmaceutical composition comprising recombinant hGH for the treatment of growth hormone deficiency
US12233113B2 · kind B2 · utility
0Cited by
3References
4Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Feb 16, 2017 |
| Grant date | Feb 25, 2025 |
| Priority date | — |
| Expiry date | Jul 19, 2040 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P5/06
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided are a method for administering a recombinant human growth hormone GX-H9 for treating growth hormone deficiency and a pharmaceutical composition containing a recombinant human growth hormone GX-H9 and a pharmaceutically acceptable carrier. The method includes administering recombinant human growth hormone GX-H9 once a week with a dosage of 0.1 to 0.3 mg per weight kg of a patient or twice-monthly with a dosage of 0.1 to 0.4 mg per weight kg of the patient.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.